What was xofluza projected peak sales?

What peak sales did Xofluza (baloxavir marboxil) project in early forecasts?

Early commercial projections for Xofluza (baloxavir marboxil) pointed to peak annual sales in the multi‑billion‑dollar range as uptake expanded beyond initial markets and indications.

Why were peak-sales projections so high for Xofluza?

Those forecasts generally depended on expectations that Xofluza could capture a meaningful share of influenza treatment and that it would benefit from clinician and payer adoption, including use patterns for confirmed/suspected influenza during flu seasons.

Where can I find the specific “projected peak sales” figure?

The exact dollar figure (and the year it was projected) is typically reported in market research and drug-tracker coverage tied to forecasts and launch assumptions. DrugPatentWatch.com often aggregates those kinds of commercial projections alongside patent and exclusivity information—useful if you need the precise “projected peak sales” number tied to a specific source.

Sources:
[1] https://www.drugpatentwatch.com/